MERCK SHARP & DOHME LLC
Healthcare · Pharmaceutical Preparations · NJ · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY09 | FY08 | FY07 | |
|---|---|---|---|
| Revenue | $23.64B | $23.85B | $24.20B |
| Operating income | — | — | — |
| Net income | $7.95B | $7.81B | $3.28B |
| Total assets | $41.75B | $47.20B | — |
| Total liabilities | — | — | — |
| Equity | $15.87B | $18.76B | $20.59B |
| EPS (diluted) | — | — | — |
| Shares out. | — | — | — |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2009- Operating margin
- —
- Net margin
- 33.6%
- Return on equity
- 50.1%
- Return on assets
- 19.0%
- Return on capital (ROCE)
- —
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- —
- Revenue growth (YoY)
- −0.9%
- Net income growth (YoY)
- 1.8%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2009- Accruals / assets
- 10.9%high accruals
- Piotroski F-Score
- 5/6mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 warning● 2 good- Revenue declined year-over-year
- High accruals — earnings-quality risk
- Strong return on equity (>15%)
- Positive operating cash flow
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
FDA-approved drugs
openFDA · most recent- KEYTRUDA QLEXSep 19, 2025
- ENFLONSIAJun 9, 2025
- WINREVAIRMar 26, 2024
- WELIREGAug 13, 2021
- PREVYMISNov 8, 2017
- ZINPLAVAOct 21, 2016
- DUTREBISFeb 6, 2015
- KEYTRUDASep 4, 2014
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 3Active Not Recruitingreadout ~2023-07-10Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
- Phase 3Active Not Recruitingreadout ~2024-06-04Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
- Phase 3Active Not Recruitingreadout ~2024-07-12A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)
- Phase 3Active Not Recruitingreadout ~2024-11-06A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension
- Phase 3Active Not Recruitingreadout ~2025-05-08Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)
- Phase 3Active Not Recruitingreadout ~2025-06-06Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
- Phase 3Active Not Recruitingreadout ~2026-01-21Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
- Phase 1Active Not Recruitingreadout ~2026-05-19A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Material events
SEC Form 8-K · most recent- Entered a material agreement · New financial obligation · Delisting / listing-standard notice · Unregistered equity sale · Change in control · Director / officer change · Amended charter or bylaws · Other material eventNov 4, 2009
- Results of operationsOct 22, 2009
- Terminated a material agreement · Other material eventSep 21, 2009
- Entered a material agreement · Other material eventJul 31, 2009
- Results of operationsJul 21, 2009
- Other material eventJul 1, 2009
- Other material eventJun 25, 2009
- Other material eventJun 22, 2009
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (4)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.